New Technology– category –
-
Prelude Therapeutics Receives IND Clearance for Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer Phase 1 Study
MarketBeat USA Overview On September 10, 2026, Prelude Therapeutics announced FDA Investigational New Drug (IND) clearance for PRT13722, an oral KAT6A selective degrader. This compound is being developed for HR-positive/HER2-negative bre... -
FDA Approves Multiple Novel Cancer Therapeutics, Including Multi-Selective RAS(ON) Inhibitor Daraxonrasib and Next-Gen ADCs for Difficult-to-Treat Cancers
The ASCO Post USA Overview The U.S. FDA announced several groundbreaking cancer drug approvals on September 10, 2026, including daraxonrasib, a multi-selective RAS(ON) inhibitor, for metastatic pancreatic adenocarcinoma. Other approvals ... -
WuXi XDC Out-Licenses WuXiTecan-2 Linker-Payload Technology to Ona Therapeutics to Accelerate ADC Development
PR Newswire China Overview WuXi XDC announced the out-licensing of its innovative WuXiTecan-2 linker-payload technology platform to Ona Therapeutics, a Spanish biotechnology company, to advance novel Antibody-Drug Conjugate (ADC) researc... -
FDA Approves Vertex’s Zanvastro: First Disease-Modifying ASO Therapy for Alexander Disease
Healio USA Overview The U.S. FDA has approved Zanvastro (zilgannersen), an antisense oligonucleotide (ASO) therapy from Vertex Pharmaceuticals, for pediatric and adult patients with Alexander disease. This marks the first disease-modifyi... -
Oral GLP-1 Receptor Agonists Foundayo (Orforglipron) and Wegovy Pill (Oral Semaglutide) Demonstrate Average Weight Loss of 12.4% and 16.6% Respectively by 2026
PrivateDoc® Unknown Overview By 2026, two oral GLP-1 receptor agonists, Foundayo (orforglipron) and Wegovy pill (oral semaglutide), are approved for weight management in the UK. Foundayo, a small-molecule non-peptide, can be taken with o... -
Novel Bispecific Antibodies Pumitamig, PF-08634404, and INCA033890-303 Advance to Phase 3 in Colorectal Cancer Trials
Fight Colorectal Cancer USA Overview The September 2026 Colorectal Cancer (CRC) clinical trial roundup highlights several promising Phase 3 studies featuring novel bispecific antibodies. These include pumitamig (targeting PD-L1 and VEGF-... -
Google DeepMind’s AlphaFold 3 Achieves Unprecedented Accuracy in Predicting Molecular Interactions, Driving AI-Discovered Drugs to Phase III Trials
New Market Pitch Unknown Overview AI drug discovery is now fully functional in structural prediction, molecular design, lead optimization, and protein engineering. Google DeepMind and Isomorphic Labs' AlphaFold 3 demonstrates superior ac... -
Eli Lilly’s Foundayo® (Orforglipron) Receives FDA Approval as First Oral Non-Peptide GLP-1 Receptor Agonist, Demonstrates Significant Weight Loss and Cardiometabolic Improvement
Obesity Medicine Review Unknown Overview Eli Lilly's Orforglipron, branded as Foundayo®, has received FDA approval as the latest oral GLP-1 receptor agonist. Distinguishing itself from oral semaglutide (Wegovy®) as a small-molecule, non-... -
Ivonescimab Significantly Improves Overall Survival vs. Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC
The ASCO Post Unknown Overview Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to pembrolizumab as a first-line... -
BioNTech Announces gotistobart Phase III Achieves Median OS of 18.5 Months in Squamous NSCLC at WCLC 2026
european biotechnology Germany Overview At the World Conference on Lung Cancer (WCLC) 2026 in Seoul, BioNTech presented pivotal data from the Phase III PRESERVE-003 trial for gotistobart (BNT316/ONC-392), a pH-sensitive anti-CTLA-4 antib...
